Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 1/20 | 0.46 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4608649 | 0.85 | DDB1 (0.50) | DDB1CRBN | |
| SCHEMBL6297349 | 0.79 | DDB1 (0.44) | DDB1CRBNKMT2A | |
| SCHEMBL4609023 | 0.76 | DDB1 (0.54) | DDB1CRBNALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL4272254 | 0.76 | DDB1 (0.51) | DDB1CRBNALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL27675507 | 0.76 | DDB1 (0.51) | DDB1CRBNALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL6303603 | 0.75 | DDB1 (0.48) | DDB1CRBNALDH1A1 | |
| SCHEMBL10554096 | 0.74 | DDB1 (0.47) | DDB1CRBNALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL10555922 | 0.74 | DDB1 (0.47) | DDB1CRBNALDH1A1 | |
| SCHEMBL20156647 | 0.74 | DDB1 (0.46) | DDB1CRBNALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL15254066 | 0.74 | DDB1 (0.46) | DDB1CRBNALDH1A1MAPK1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050143453-A1 | Selective preventing and therapeutic agents for progressive lesion after organic damage | ISHIBASHI MICHIO (JP) | 2005-06-30 | — | — | US | disclosed |
| US-6878745-B2 | Selective preventives/remedies for progressive lesions after organ damage | Ishibashi, Michio (JP) | 2005-04-12 | — | — | US | disclosed |
| US-20030181506-A1 | Selective preventives/remedies for progressive lesions after organ damage | ISHIBASHI, MICHIO (JP) | 2003-09-25 | — | — | US | disclosed |
| EP-1277747-A1 | SELECTIVE PREVENTIVES/REMEDIES FOR PROGRESSIVE LESIONS AFTER ORGAN DAMAGE | Ishibashi, Michio (JP) | 2003-01-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181506-A1 | Selective preventives/remedies for progressive lesions after organ damage | CCL11, CD68, CCL2 | DDB1 495/4885CRBN 4234/4885ALDH1A1 750/4885 |
| US-20050143453-A1 | Selective preventing and therapeutic agents for progressive lesion after organic damage | CD68, MSR1, CCL2 | DDB1 578/4885CRBN 3895/4885ALDH1A1 484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.